1-4 of 4
Stefan Oertel
Close
Sort by
Journal Articles

Safety and Efficacy in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Early Results From Phase IIIb MAXIMA Trial.

Mathias Witzens-Harig, Guy van Hazel, Dalton FA Chamone, Klaus Ruffert, Jacob M. Rowe, Mario Lazzarino, Robin Foà, Irina Poddubnaya, Anthony D. Ho, Valentina Ivanova, Andrej Vranowsky, Joachim Hipp, Stefan Oertel
Journal: Blood
Blood (2009) 114 (22): 3756.
https://doi.org/10.1182/blood.V114.22.3756.3756
Published: 2009
Journal Articles

Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial.

Mathias Witzens-Harig, Joachim Hipp, Anthony D. Ho, Nikolai Nikolov, Daniel Thurley, Manfred Hensel, MD, Stefan Oertel, Michael Wenger
Journal: Blood
Blood (2008) 112 (11): 1998.
https://doi.org/10.1182/blood.V112.11.1998.1998
Published: 2008
Journal Articles

Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R)

Sylvain Choquet, Stefan Oertel, Ioannis Anagnostopoulos, Hanno Riess, Madalina Uzunov, V.éronique Leblond, Ralf Trappe
Journal: Blood
Blood (2008) 112 (11): 3614.
https://doi.org/10.1182/blood.V112.11.3614.3614
Published: 2008
Journal Articles

Analysis of EBV-Specific T Cell Responses in Transplant Recipients with PTLD.

Kathrin Sebelin, Antje Meier, Matthias Papp-Vary, MD, Stefan Oertel, MD, Antonio Pezzutto, MD, Bernd Doerken, MD, Hanno Riess, MD, Marion Subklewe, MD
Journal: Blood
Blood (2005) 106 (11): 1915.
https://doi.org/10.1182/blood.V106.11.1915.1915
Published: 2005